Core Scientific Temettüler ve Geri Alımlar
Temettü kriter kontrolleri 0/6
Core Scientific şirketinin temettü ödeme geçmişi bulunmamaktadır.
Anahtar bilgiler
n/a
Temettü verimi
0.4%
Geri Alım Getirisi
| Toplam Hissedar Getirisi | 0.4% |
| Gelecekteki Temettü Verimi | 0% |
| Temettü Büyümesi | n/a |
| Bir sonraki temettü ödeme tarihi | n/a |
| Eski temettü tarihi | n/a |
| Hisse başına temettü | n/a |
| Ödeme oranı | n/a |
Son temettü ve geri alım güncellemeleri
Güncelleme yok
Recent updates
CORZ: AI Hosting Ramp And Power Buildout Are Expected To Drive Upside
Analysts have adjusted the Core Scientific fair value estimate from $37.43 to $35.65, reflecting updated assumptions around higher projected revenue growth and profit margins, along with a lower future P/E multiple and a slightly refined discount rate based on recent research highlighting progress in AI hosting capacity, lease expectations, and HPC expansion. Analyst Commentary Recent Street research points to generally constructive sentiment around Core Scientific, with several bullish analysts refining models as new information comes through on AI hosting progress, lease timing, and high performance computing capacity.
CORZ: AI Hosting Contracts And Power Expansion Will Drive Future Upside
Analysts have raised their blended price target on Core Scientific by a few dollars, placing it in the low to mid $20s. They cite progress on AI hosting contracts, expanded power capacity, and an ongoing shift in the power portfolio from Bitcoin mining toward high performance compute.CORZ: AI Hosting Shift And Lease Pipeline Will Drive Future Upside
Analysts have nudged the Core Scientific price target slightly lower, with the updated fair value estimate moving from about $26.82 to $26.40. They are weighing higher projected revenue growth and profit margins against revised P/E assumptions and recent research highlighting organic growth plans, AI hosting expansion and an evolving lease pipeline.
CORZ: AI Hosting Expansion And Texas Power Capacity Will Drive Future Upside
Analysts lifted their Core Scientific fair value estimate to $20 from $17, pointing to progress on new Texas capacity, AI hosting expansion, and expectations around additional lease signings as key drivers behind the higher price target range across recent research updates. Analyst Commentary Street research on Core Scientific has been active, with several firms updating their views around the company’s shift toward AI and high performance compute hosting, the timing of new lease signings, and the evolving power portfolio.CORZ: Power Shift To High Performance Compute Will Support Future Contracts
Analysts have lifted their $-denominated price targets on Core Scientific, with one firm increasing its view by $6. They point to steadier discount rate assumptions, slightly higher projected revenue growth and margins, and a lower future P/E multiple supported by expectations for additional high performance compute contracts after the failed CoreWeave merger.CORZ: Power Footprint Conversion To High Performance Compute Will Drive Next Phase
Analysts have trimmed their fair value estimate for Core Scientific from US$37.71 to US$37.43, citing updated assumptions around discount rates, revenue growth, margins and future P/E after recent price target changes and research highlighting both regulatory risks for crypto and potential long term upside from high performance computing contracts. Analyst Commentary Recent Street research around Core Scientific has highlighted a mix of crypto related policy risk and optimism around the company’s push into high performance computing, with some research pointing to potential valuation upside if execution on new contracts goes to plan.CORZ: Future Compute Contracts And Crypto Exposure Balance Fair Opportunity And Risk
Narrative Update The analyst price target for Core Scientific has shifted from US$15.00 to US$17.00 as analysts factor in improved profit margin assumptions, a lower modeled discount rate, and recent research that points to potential value creation from the company pursuing high performance compute contracts following the terminated CoreWeave merger. Analyst Commentary Recent research coverage has shifted toward a more constructive tone on Core Scientific, with several firms lifting ratings and price targets following the terminated CoreWeave merger and increased focus on high performance compute opportunities.CORZ: Power Footprint And HPC Contracts Will Define Next Phase
Narrative Update: Core Scientific Analyst Price Target Move The analyst price target for Core Scientific has shifted from roughly US$23.00 to about US$37.71. Analysts attribute this change to the resolution of the CoreWeave merger overhang, a renewed focus on high performance compute colocation contracts, and the perceived value of the company’s power infrastructure.Core Scientific: Buying This AI Data Center Winner Into Recent Weakness
Dec 17CORZ: Standalone AI Power Pipeline Will Drive Future Upside Potential
Analysts have trimmed their fair value estimate for Core Scientific by about $0.83 per share to $26.82, reflecting a slightly higher discount rate even as they highlight improved standalone prospects, reduced deal overhang, and stronger AI infrastructure optionality as key supports for the updated price target. Analyst Commentary Recent Street research reflects a largely constructive shift in sentiment on Core Scientific, with multiple firms raising ratings and price targets as the market pivots to a standalone, AI and high performance compute oriented narrative following the termination of the CoreWeave merger.CORZ: Terminated Merger Will Unlock New Upside With Power Pipeline Expansion
Analysts have modestly raised their price target for Core Scientific to $27 from $23, citing the terminated merger and increased confidence in the company’s standalone prospects as key factors supporting improved valuation. Analyst Commentary Recent street research reflects a range of perspectives on Core Scientific's prospects as a standalone company, especially after the terminated merger.CORZ: Standalone Operator Status Will Unlock New Upside This Year
Analysts have increased their fair value price target for Core Scientific from $25.25 to $27.65. They cite renewed confidence in the company's standalone prospects and the removal of merger-related overhangs as reasons for this adjustment.CORZ: Power Portfolio And AI Demand Will Unlock Substantial Upside
Core Scientific's analyst price target has increased significantly from $20.88 to $25.25 per share. This change reflects analysts' optimism following the terminated merger with CoreWeave and improved standalone growth prospects for the company.HPC Expansion And Diversified Contracts Will Create Future Resilience
Analysts have raised their price target for Core Scientific from $19.95 to $20.88 per share, citing strong sector momentum from major data center deals and an improved profit margin outlook. Analyst Commentary Analyst discussions surrounding Core Scientific have highlighted both promising industry dynamics and company-specific considerations that could influence future performance and valuation.HPC Expansion And Diversified Contracts Will Create Future Resilience
Analysts have raised their price target for Core Scientific from $19.05 to $19.95 per share, citing updated deal terms and ongoing re-evaluation of merger economics following CoreWeave's acquisition agreement. Analyst Commentary Analysts continue to weigh the implications of Core Scientific's pending acquisition by CoreWeave, with a mix of optimism for the company's positioning and caution regarding valuation and deal structure.HPC Expansion And Diversified Contracts Will Create Future Resilience
Consensus analyst price targets for Core Scientific have risen slightly to reflect the strategic value of its infrastructure assets highlighted by the announced CoreWeave acquisition, despite some uncertainty regarding realized shareholder value and potential downside to deal economics, resulting in a revised fair value of $19.05. Analyst Commentary The announced acquisition of Core Scientific by CoreWeave in an all-stock transaction prompted widespread price target reductions and downgrades to Neutral/Hold/Perform, reflecting diminished standalone upside and uncertainty regarding the ultimate value realized by Core Scientific shareholders.
HPC Expansion And Diversified Contracts Will Create Future Resilience
Reallocating resources from Bitcoin mining to HPC infrastructure could drive future growth amid rising data center demands and diversified clientele.The AI Awakening Of Core Scientific
Mar 18DeepSeek, Market Volatility, False Rumor Create Opportunity In Core Scientific
Mar 09Core Scientific: Higher Digital Asset Prices And Making Progress On Debt
Jan 12Core Scientific: HPC Pivot Begins To Bear Fruit
Oct 16Core Scientific: Deserves Better As HPC Moves Into High Gear
Aug 13Core Scientific: HPC Deals And A Buyout Offer
Jun 04Ödemelerde İstikrar ve Büyüme
Temettü verilerini getirme
İstikrarlı Temettü: CORZ şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.
Büyüyen Temettü: CORZ şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.
Piyasaya Karşı Temettü Getirisi
| Core Scientific Piyasaya Karşı Temettü Getirisi |
|---|
| Segment | Temettü Verimi |
|---|---|
| Şirket (CORZ) | n/a |
| Pazarın Alt %25'i (US) | 1.4% |
| Pazarın En İyi %25'i (US) | 4.2% |
| Sektör Ortalaması (Software) | 1.0% |
| Analist tahmini (CORZ) (3 yıla kadar) | 0% |
Önemli Temettü: CORZ şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.
Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, CORZ şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.
Hissedarlara Ödenen Kazanç
Kazanç Kapsamı: CORZ şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.
Hissedarlara Nakit Ödeme
Nakit Akışı Kapsamı: CORZ herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.
Güçlü temettü ödeyen şirketleri keşfedin
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/04/30 13:58 |
| Gün Sonu Hisse Fiyatı | 2026/04/30 00:00 |
| Kazançlar | 2025/12/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Core Scientific, Inc. 21 Bu analistlerden 15, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Ramsey El-Assal | Barclays |
| Gautam Chhugani | Bernstein |
| Nicholas Giles | B. Riley Securities, Inc. |